Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, October 26, 2026

Back to today

Merger Monday & Election Implications

EQT’s $50 billion merger with Range Resources and Ovintiv’s $1.26 billion acquisition of Logan Energy reshape North American oil and gas alongside Brazil and British Columbia election…

EQT $34BRRC $13B
Bison Insights 7 clicks

From X

@ACapitalLP 3 clicks

A Capital on X

Interesting special situation in $AKER.NO, which owns ~23% of Nscale. Despite the carnage in neoclouds, the FT reported last week that Nscale may still be targeting a $30–35bn IPO before year-end. What makes this interesting is the valuation disconnect. At ~NOK 1,150, backing out Aker’s other holdings and applying its historical ~22% HoldCo discount implies an ~$11bn valuation for Nscale. Below its $14.6bn March round and well below the proposed IPO range. In September, Third Point led a $3.36bn pre-IPO convertible financing alongside Nvidia, Apollo, Citadel and others. The notes reportedly convert at a double-digit discount to the IPO price, with a $30bn valuation cap on the conversion price. Not exactly a group of unsophisticated investors… At a $25–30bn IPO, I get ~27–39% upside assuming some HoldCo discount compression. Even at a $15bn IPO, the downside looks relatively contained under a historical discount assumption. Obviously the IPO could slip, financing and execution risks are enormous, and the broader neocloud unwind isn’t helping. But you can partially hedge the sector exposure with $CRWV / $NBIS shorts, leaving a more isolated bet on the IPO valuation and HoldCo discount...
@StableBread 1 click

Fajasy on X

Boost Run $BRUN said on October 26 that it has closed "more than $600 million in non-dilutive project financing" so far in 2026. In my October 19 update, I said the stock depends less on demand than on whether $BRUN can finance the next ~$1B of GPUs without selling shares at beaten-down prices. The release also says: → $BRUN has established "a fully funded runway to accelerate customer deployments through the fourth quarter of 2026," with additional financing "proceeding as planned." → $BRUN delivered the first phase of a multi-phase project to "a leading AI research and product company," which matches its $471.7M May 2026 contract with Thinking Machines Lab (Mira Murati's AI startup). → Several more projects are "nearing hand-off in the coming weeks." → Founder and CEO Andrew Karos: "Customer payments exceed our debt payments every month." The $600M+ is YTD, and lessors funded $268.3M of new GPU leases in H1 2026 alone. So if those leases count toward the $600M+, $BRUN has closed more than $331.7M since June 30, about half to almost two-thirds of the $527-686M of new leases I estimated its H2 2026 build needs. The release doesn't say what the financing costs or how much of it closed since June 30. However, the Q3 10-Q, expected in mid-November, should disclose how much $BRUN leased in Q3 and at what rate. If the 10-Q confirms the $600M+, I'd drop the $62.2M stock sale from my bear case, and the question shifts from whether $BRUN can fund its build to what the new debt costs.

Investor Letters

All letters

Molina & Kinsale

Molina Healthcare and Kinsale Capital’s earnings are reassessed through a long-term lens, emphasizing conviction and detachment during…

MOH $11BKNSL $8.3B
Bearstone 8 clicks

Namib Minerals: Research Flash

Namib Minerals’ How Mine mill reached 55,000 tonnes per month, 36% above prior capacity, while a proposed $30 million Ecobank facility…

NAMM $45M
Atrium Research - Equity Research 2 clicks

Bimergen Energy: Research Flash

Bimergen Energy filed for a Texas retail-power license to supply data centers directly and gained eligibility for federal contracts through…

BESS $15M
Atrium Research - Equity Research 3 clicks
SLS · short

Sellas Life Sciences Group I

SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.

SLS $2.1B
Value Investors Club

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $2B
John Hempton's Newsletter 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 67 of 265

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.